 Innate Pharma SA NASDAQ:IPHA stock closed almost 14 higher on Thursday after the Company disclosed two upcoming presentations scheduled at ESMO 2021 Virtual Congress. The presentations include a late-breaker abstract on a Phase 2 trial highlighting the progression-free survival data for monalizumab combination therapy in non-small cell lung cancer NSCLC. 